TXG's Profit Timeline Keeps Stretching While Analysts Pretend Revenue Growth Still Matters

10x Genomics reports first-quarter 2026 earnings tomorrow after the close, with Wall Street expecting another quarterly loss as the genomics tools provider navigates a challenging environment for life sciences spending. The company has beaten estimates in four consecutive quarters, but analysts are watching whether management can sustain momentum amid broader sector headwinds and deliver on its full-year guidance of $600–625 million in revenue.

Part 1: Earnings Preview

10x Genomics develops and manufactures integrated systems for analyzing biological information at the single-cell level, serving researchers in oncology, immunology, and neuroscience. The company's platforms enable high-resolution analysis of genes, proteins, and immune repertoires, positioning it as a key player in the genomics tools and services market.

The company reports Q1 2026 earnings on May 7 after market close, with analysts expecting a loss of $0.27 per share on revenue estimates around $146.55 million. In the most recently reported quarter (Q4 2025), 10x Genomics posted a loss of $0.13 per share, beating the consensus estimate of $0.19. Compared to the same quarter last year (Q1 2025), when the company reported a loss of $0.36 per share, the current estimate of $0.27 represents a 25% improvement year-over-year.

Three key themes define this earnings story:

• Revenue trajectory and guidance reaffirmation: After posting $166 million in Q4 revenue (flat year-over-year), investors are focused on whether 10x can deliver on its full-year 2026 guidance of $600–625 million. The Q1 estimate of $146.55 million represents a 5.4% decline from $154.88 million in Q1 2025, raising questions about whether the company can accelerate growth through the year.

• Life sciences spending environment: The broader genomics tools sector has faced headwinds from reduced biotech funding and cautious research budgets. Analysts are watching for commentary on customer demand trends, instrument placements, and consumables pull-through rates as indicators of whether the spending environment is stabilizing or deteriorating further.

• Path to profitability: With consensus estimates projecting a full-year 2026 loss of $0.82 per share (compared to $0.43 in 2025), the trajectory toward breakeven remains a critical focus. Management's ability to balance growth investments with expense discipline will be scrutinized, particularly given the company's history of volatile quarterly results.

Heading into the release, analyst commentary reflects cautious optimism tempered by sector concerns. The consensus has improved modestly over the past 30 days, with EPS estimates for Q1 moving from $0.36 to $0.27, suggesting analysts have become more constructive on near-term execution. However, the wide range of estimates—from a low of $0.41 loss to a high of $0.06 loss—underscores significant uncertainty about the quarter's outcome.

Part 2: Historical Earnings Performance

10x Genomics has established a strong pattern of beating earnings estimates, with the company exceeding consensus in each of the past four quarters. The magnitude of these beats has been substantial: Q4 2025 delivered a 31.58% surprise, Q3 posted an 18.52% beat, and Q2 2025 produced a remarkable 180% surprise with actual EPS of $0.28 versus an expected loss of $0.35. Even Q1 2025, with a loss of $0.36 against estimates of $0.45, represented a 20% beat.

The trend shows improving underlying performance on an absolute basis. The company's reported losses have narrowed sequentially from $0.36 in Q1 2025 to $0.13 in Q4 2025, demonstrating progress toward profitability despite the challenging operating environment. The Q2 2025 result stands out as an anomaly—the only profitable quarter in recent history—suggesting either one-time benefits or significant operational leverage that has not yet proven sustainable.

This consistent outperformance relative to estimates suggests either conservative analyst modeling or genuine operational momentum that Wall Street has underestimated. Given the pattern, investors may be pricing in another beat tomorrow, which raises the bar for a positive stock reaction. The question is whether 10x can continue exceeding expectations while also providing guidance that supports the full-year outlook.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

10x Genomics reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around earnings shows moderate volatility with mixed directional bias. On Day 0 (the session before results), the stock has moved an average of 3.76% in absolute terms with a typical range of 6.50%, reflecting pre-announcement positioning. Day +1 reactions have been larger, averaging 5.49% with a much wider 14.45% range, indicating that the market's initial response to actual results can be substantial.

The most recent earnings cycle (February 2026) produced the largest Day 0 move in the dataset—an 8.56% decline—followed by a 3.48% recovery on Day +1, suggesting initial pessimism that reversed once results were digested. In contrast, the November 2025 report saw a modest 3.63% Day 0 decline followed by a sharp 17.31% Day +1 rally, the strongest post-earnings gain in recent history. This pattern suggests that actual results and guidance matter more than pre-announcement speculation, with the market frequently repricing the stock significantly in the session following the release. Investors should be prepared for potential double-digit percentage swings in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.17% expected move through the May 15 expiration, implying a range of $19.52 to $25.96. This is notably higher than the stock's average Day +1 historical move of 5.49% but well within the 14.45% average Day +1 range, suggesting options traders are anticipating above-average volatility but not an outlier event. The elevated implied volatility of 131.83% reflects significant uncertainty about the quarter's outcome and management's guidance.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on 10x Genomics heading into earnings, with a consensus rating of 3.82 (between Hold and Buy) and an average price target of $24.00. This target implies 5.5% upside from the current price of $22.74, suggesting modest appreciation potential if the company meets expectations.

The analyst community is split, with 7 Strong Buy ratings and 10 Hold ratings among the 17 analysts covering the stock. Notably, there are no Sell or Strong Sell ratings, indicating that even skeptics see limited downside risk at current levels. The price target range is wide—from a low of $17.00 to a high of $32.00—reflecting divergent views on the company's growth trajectory and path to profitability.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 6 to 7 and the average recommendation ticking up from 3.71 to 3.82. This modest upgrade suggests analysts are becoming more constructive as the earnings date approaches, possibly reflecting confidence in the company's ability to deliver another beat or provide encouraging guidance. The shift indicates that Wall Street is giving 10x Genomics credit for recent execution improvements while remaining cautious about the broader life sciences spending environment.

Part 4: Technical Picture

The Barchart Technical Opinion stands at 80% Buy, up from 64% Buy a week ago and down slightly from 88% Buy a month ago, indicating a strengthening near-term signal after a brief pullback. This improvement suggests technical momentum is building heading into the earnings release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, suggesting some consolidation or mixed trading in recent sessions
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe reflects solid upward momentum over the past several weeks
• Long-term (100% Buy): Strong buy signal in the longer-term trend indicates the stock has established a sustained uptrend over multiple months

Trend Characteristics: The Strong and Strengthening trend environment suggests technical momentum is building into earnings, with the stock positioned favorably across multiple timeframes despite some near-term hesitation.

The stock is trading at $22.74, above its 5-day ($22.18), 10-day ($21.82), 50-day ($21.51), 100-day ($20.17), and 200-day ($17.09) moving averages, but below its 20-day average ($23.00). This configuration indicates a well-established uptrend with the stock having pulled back modestly from recent highs near the 20-day level.

The technical setup is supportive heading into earnings, with the stock holding above all major long-term moving averages and showing strength across medium- and long-term timeframes. The recent pullback to just below the 20-day moving average could provide a constructive entry point if results and guidance are well-received. However, the modest short-term signal (50% Buy) suggests some caution is warranted, as the stock may need a strong earnings beat and positive guidance to break back above the $23 level and resume its uptrend. The combination of improving technical momentum and proximity to support levels creates a setup where a positive surprise could trigger a sharp move higher, while a disappointment might find support near the 50-day average around $21.50.